Sage Therapeutics IncEquity-NMS: SAGE
Equity-NMS: SAGE
$21.86
+0.38
(3 Mar)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$21.86
Open
$21.86
Today’s high
$22.17
Today’s low
$21.42
52W low
$16.52
52W high
$59.99
1Y
-47.69%
5Y
-32.73%
PE
-2.38
EPS (TTM)
-9.05
Shares O/S
60.11M
Market cap
1.31B
Insights
SAGE is in the lowest 10% returns in the past year. It is a low momentum stock. Low momentum stocks tend to underperform in the near term.
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Sage Therapeutics Inc

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults.

ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor. .


FAQs

Can I buy Sage Therapeutics Inc shares in India?
How to buy Sage Therapeutics Inc shares in India?
What is the share price of Sage Therapeutics Inc?
What is the Market Capitalization of Sage Therapeutics Inc?
What is the PE ratio of Sage Therapeutics Inc?
Is Sage Therapeutics Inc a good stock to buy?
In which sector / industry does Sage Therapeutics Inc operate?